Skip to content Skip to footer
Subscribe Now
Viewpoints_Michael Dale
VIEWPOINTS

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System

In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor's approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery. Shots: Abbott has received CE Mark approval for its latest-generation transcatheter aortic…
September 3, 2021

Read more

Insights+ Key Biosimilars Events of August 2021
INSIGHTS+

Insights+ Key Biosimilars Events of August 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of August, Samsung Bioepis Byooviz (biosimilar, ranibizumab) received EC's…
September 2, 2021

Read more

Viewpoints_Rami Levin
VIEWPOINTS

PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity

In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA's Orphan Drug Designation (ODD) to Tesomet for the treatment of hypothalamic obesity (HO) and discuss its role in the company's continued pipeline progress. Shots: Saniona reported that the FDA has granted orphan drug designation to Tesomet for the…
August 27, 2021

Read more

Thoughtspot_Senior Editor
THOUGHTSPOT

Over Prescribed Medications and its Impact

Introduction: 'Over-prescription' is defined as the action of prescribing a drug or treatment in greater amount or on more occasions than necessary. Overprescribing, in general in health care, has been a subject of frequent study. For instance, research published in 2018 found that 46% of a half-million outpatient antibiotic prescriptions were written by clinicians without diagnoses of…
August 26, 2021

Read more

Viewpoints_Avanish Vellanki
VIEWPOINTS

PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the Initiation of P-III MANTRA Trial of Milademetan for Dedifferentiated Liposarcoma

In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company's lead candidate, RAIN-32. Shots: The company initiates P-III MANTRA trial to evaluate safety & efficacy of…
August 23, 2021

Read more

Viewpoints_Jonathan Rigby
VIEWPOINTS

PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis

In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of '1104 and discuss the plan of the company's clinical studies. Shots: Revolo reported the US FDA's approval to initiate a P-II clinical trial evaluating the safety and efficacy of '1104 in adults with EoE '1104 is a…
August 18, 2021

Read more

Viewpoints_Jonathan Rigby
VIEWPOINTS

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease

In an interview with PharmaShots, Andrew Greenspan, VP, Immunology Affairs at Janssen shared his views on the new AGA guidelines on the medical management of moderate-to-severe Crohn's disease and also highlighted about Janssen's efforts in improving the QoL of patients with CD The AGA guidelines assessed the overall benefit of each drug and also compared…
August 17, 2021

Read more

Viewpoints_Dennis Williams
VIEWPOINTS

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market

In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors.…
August 16, 2021

Read more

Viewpoints_Konstantin Mehl
VIEWPOINTS

PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD

In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU. Shots: The funding will extend the offering within EU and…
August 11, 2021

Read more

Load more